Segall Bryant & Hamill LLC Decreases Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Segall Bryant & Hamill LLC lowered its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 22.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 351,339 shares of the biotechnology company’s stock after selling 99,936 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in ADMA Biologics were worth $7,023,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Quest Partners LLC acquired a new stake in ADMA Biologics in the 2nd quarter valued at about $29,000. Hollencrest Capital Management acquired a new position in ADMA Biologics during the 3rd quarter worth approximately $30,000. EntryPoint Capital LLC acquired a new stake in shares of ADMA Biologics in the 1st quarter valued at $31,000. CWM LLC lifted its position in shares of ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of ADMA Biologics during the second quarter worth $93,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the transaction, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. This trade represents a 10.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Jerrold B. Grossman sold 136,861 shares of the business’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $17.27, for a total value of $2,363,589.47. Following the completion of the transaction, the director now owns 467,305 shares in the company, valued at $8,070,357.35. This trade represents a 22.65 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 406,900 shares of company stock worth $7,128,521 in the last 90 days. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Stock Down 0.3 %

ADMA opened at $21.30 on Friday. The stock has a market capitalization of $5.04 billion, a P/E ratio of 76.07 and a beta of 0.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a one year low of $3.60 and a one year high of $23.64. The business’s 50-day simple moving average is $18.72 and its 200-day simple moving average is $14.69.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter in the previous year, the business earned $0.01 earnings per share. Analysts anticipate that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. HC Wainwright raised their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a report on Friday, September 20th. Finally, Raymond James raised their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.